
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2945236/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Late-life cynical hostility is associated with white matter alterations and the risk of Alzheimer's disease. Psychological Medicine, 2022, 52, 3636-3645.	4.5	2
2	The Association of Weight Loss, Weight Status, and Abdominal Obesity with All-Cause Mortality in Older Adults. Gerontology, 2022, 68, 1366-1374.	2.8	9
3	The association between adverse childhood events and later-life cognitive function and dementia risk. Journal of Affective Disorders, 2022, 304, 128-132.	4.1	5
4	Time-dependent cognitive and somatic symptoms of depression as predictors of new cardiac-related events in at-risk patients: the UPBEAT-UK cohort. Psychological Medicine, 2021, 51, 1271-1278.	4.5	9
5	11β-Hydroxylase ( <i>CYP11B1</i> ) gene variants and new-onset depression in later life. Journal of Psychiatry and Neuroscience, 2021, 46, E147-E153.	2.4	6
6	Time-dependent depression and anxiety symptoms as risk factors for recurrent cardiac events: findings from the UPBEAT-UK study. Psychological Medicine, 2021, , 1-9.	4.5	2
7	Steroid 21-hydroxylase gene variants and late-life depression. BMC Research Notes, 2021, 14, 203.	1.4	0
8	Structural brain alterations in older adults exposed to early-life adversity. Psychoneuroendocrinology, 2021, 129, 105272.	2.7	14
9	A Prospective Study of Diurnal Cortisol and Incident Dementia in Community-Dwelling Older Adults. Journal of Alzheimer's Disease, 2021, 82, 899-904.	2.6	1
10	Aromatase ( <i>CYP19A1</i> ) gene variants, sex steroid levels, and lateâ€life depression. Depression and Anxiety, 2020, 37, 146-155.	4.1	10
11	The extent to which childhood adversity and recent stress influence all-cause mortality risk in older adults. Psychoneuroendocrinology, 2020, 111, 104492.	2.7	29
12	Does parity matter in women's risk of dementia? A COSMIC collaboration cohort study. BMC Medicine, 2020, 18, 210.	5.5	21
13	The long-term consequences of trauma and posttraumatic stress disorder symptoms on later life cognitive function and dementia risk. Psychiatry Research, 2020, 294, 113506.	3.3	15
14	A crossâ€national study of depression in preclinical dementia: A COSMIC collaboration study. Alzheimer's and Dementia, 2020, 16, 1544-1552.	0.8	8
15	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimer's Research and Therapy, 2020, 12, 167.	6.2	64
16	Is Peripheral BDNF Promoter Methylation a Preclinical Biomarker of Dementia?. Journal of Alzheimer's Disease, 2020, 73, 645-655.	2.6	9
17	Structural brain changes with lifetime trauma and re-experiencing symptoms is <i>5-HTTLPR</i> genotype-dependent. Högre Utbildning, 2020, 11, 1733247.	3.0	4
18	Testosterone Level and Cause-Specific Mortality in Older Men without Metabolic Syndrome. Epidemiology and Health, 2020, 42, e2020036.	1.9	1

#	Article	IF	CITATIONS
19	Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. PLoS Medicine, 2019, 16, e1002853.	8.4	86
20	Sex-specific depressive symptoms as markers of pre-Alzheimer dementia: findings from the Three-City cohort study. Translational Psychiatry, 2019, 9, 291.	4.8	11
21	Increased Serum C-reactive Protein and Corpus Callosum Alterations in Older Adults. , 2019, 10, 463.		6
22	Genetic and Epigenetic Regulation of the Serotonin Transporter Gene in Late-Life Depression. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 175-177.	2.3	6
23	Lifetime major depression and grey-matter volume. Journal of Psychiatry and Neuroscience, 2019, 44, 45-53.	2.4	69
24	Association between DNA methylation of the <i>KITLG</i> gene and cortisol levels under stress: a replication study. Stress, 2019, 22, 162-168.	1.8	11
25	Frequent attendance and the concordance between PHQ screening and GP assessment in the detection of common mental disorders. Journal of Psychosomatic Research, 2018, 110, 1-10.	2.6	Ο
26	5-HTTLPR × stress hypothesis: is the debate over?. Molecular Psychiatry, 2018, 23, 2116-2117.	7.9	15
27	Testosterone and All-Cause Mortality in Older Men: The Role of Metabolic Syndrome. Journal of the Endocrine Society, 2018, 2, 322-335.	0.2	14
28	DNA methylation and genetic variation of the angiotensin converting enzyme (ACE) in depression. Psychoneuroendocrinology, 2018, 88, 1-8.	2.7	13
29	Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies. PLoS Medicine, 2018, 15, e1002704.	8.4	81
30	Genotype-dependent associations between serotonin transporter gene (SLC6A4) DNA methylation and late-life depression. BMC Psychiatry, 2018, 18, 282.	2.6	56
31	Oestradiol level, oestrogen receptors, and mortality in elderly men: The threeâ€city cohort study. Clinical Endocrinology, 2018, 89, 514-525.	2.4	6
32	Chronic and remitting trajectories of depressive symptoms in the elderly. Characterisation and risk factors. Epidemiology and Psychiatric Sciences, 2017, 26, 146-156.	3.9	21
33	The effect of an adverse psychological environment on salivary cortisol levels in the elderly differs by 5-HTTLPR genotype. Neurobiology of Stress, 2017, 7, 38-46.	4.0	11
34	Preliminary evidence for a role of the adrenergic nervous system in generalized anxiety disorder. Scientific Reports, 2017, 7, 42676.	3.3	13
35	Antidepressant use and cognitive decline in community-dwelling elderly people – The Three-City Cohort. BMC Medicine, 2017, 15, 81.	5.5	14
36	Heterogeneity in HPA axis dysregulation and serotonergic vulnerability to depression. Psychoneuroendocrinology, 2017, 77, 90-94.	2.7	69

#	Article	IF	CITATIONS
37	Investigating the epigenetic profile of the inflammatory gene IL-6 in late-life depression. BMC Psychiatry, 2017, 17, 354.	2.6	31
38	Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. PLoS Medicine, 2017, 14, e1002261.	8.4	120
39	Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. PLoS Medicine, 2017, 14, e1002265.	8.4	79
40	Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort. Osteoporosis International, 2016, 27, 3187-3195.	3.1	20
41	Biological and psychological predictors of posttraumatic stress disorder onset and chronicity. A one-year prospective study. Neurobiology of Stress, 2016, 3, 61-67.	4.0	29
42	Biological underpinnings of trauma and post-traumatic stress disorder: focusing on genetics and epigenetics. Epigenomics, 2016, 8, 1553-1569.	2.1	55
43	Impact of sleep disturbances on kidney function decline in the elderly. European Respiratory Journal, 2016, 47, 860-868.	6.7	18
44	GWAS-identified risk variants for major depressive disorder: Preliminary support for an association with late-life depressive symptoms and brain structural alterations. European Neuropsychopharmacology, 2016, 26, 113-125.	0.7	41
45	The Clinical Picture of Alzheimer's Disease in the Decade Before Diagnosis. Journal of Clinical Psychiatry, 2016, 77, e305-e311.	2.2	50
46	Involvement of <scp>GPR</scp> 50 polymorphisms in depression: independent replication in a prospective elderly cohort. Brain and Behavior, 2015, 5, e00313.	2.2	14
47	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS ONE, 2015, 10, e0142388.	2.5	225
48	Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ, The, 2015, 350, h2335-h2335.	6.0	35
49	Elderly Benzodiazepine Users at Increased Risk of Activity Limitations: Influence of Chronicity, Indications, and Duration of Action—The Three-City Cohort. American Journal of Geriatric Psychiatry, 2015, 23, 840-851.	1.2	19
50	C-reactive protein gene variants: independent association with late-life depression and circulating protein levels. Translational Psychiatry, 2015, 5, e499-e499.	4.8	35
51	BDNF promoter methylation and genetic variation in late-life depression. Translational Psychiatry, 2015, 5, e619-e619.	4.8	111
52	Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (The ESPRIT study). Translational Psychiatry, 2015, 5, e536-e536.	4.8	49
53	Generalized anxiety in community-dwelling elderly: Prevalence and clinical characteristics. Journal of Affective Disorders, 2015, 172, 24-29.	4.1	59
54	The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS ONE, 2015, 10, e0142388.	2.5	5

#	Article	IF	CITATIONS
55	Metabolic Syndrome and Disability: Findings From the Prospective Three-City Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 79-86.	3.6	47
56	High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology, 2014, 82, 504-511.	1.1	34
57	Plasma Estrogen Levels, Estrogen Receptor Gene Variation, and Ischemic Arterial Disease in Postmenopausal Women: The Three-City Prospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1539-E1546.	3.6	15
58	Impact of a premature menopause on cognitive function in later life. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1729-1739.	2.3	140
59	Gender-specific associations between lipids and cognitive decline in the elderly. European Neuropsychopharmacology, 2014, 24, 1056-1066.	0.7	46
60	Corpus callosum size may predict late-life depression in women: A 10-year follow-up study. Journal of Affective Disorders, 2014, 165, 16-23.	4.1	15
61	The association between caffeine and cognitive decline: examining alternative causal hypotheses. International Psychogeriatrics, 2014, 26, 581-590.	1.0	15
62	Low testosterone and the risk of dementia in elderly men: Impact of age and education. Alzheimer's and Dementia, 2014, 10, S306-14.	0.8	45
63	Estrogen receptor polymorphisms and incident dementia: The prospective 3C study. Alzheimer's and Dementia, 2014, 10, 27-35.	0.8	32
64	Brain volumes in late life: gender, hormone treatment, and estrogen receptor variants. Neurobiology of Aging, 2014, 35, 645-654.	3.1	18
65	Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Medicine, 2013, 11, 212.	5.5	64
66	COSMIC (Cohort Studies of Memory in an International Consortium): An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. BMC Neurology, 2013, 13, 165.	1.8	58
67	A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: The French 3C cohort study. Maturitas, 2013, 75, 282-288.	2.4	80
68	Prospective analysis of the association between estrogen receptor gene variants and the risk of cognitive decline in elderly women. European Neuropsychopharmacology, 2013, 23, 1763-1768.	0.7	19
69	A prospective study of the bi-directional association between vision loss and depression in the elderly. Journal of Affective Disorders, 2013, 151, 164-170.	4.1	79
70	Depressive symptoms, antidepressants and disability and future coronary heart disease and stroke events in older adults: the Three City Study. European Journal of Epidemiology, 2013, 28, 249-256.	5.7	22
71	Late-Onset Agoraphobia: General Population Incidence and Evidence for a Clinical Subtype. American Journal of Psychiatry, 2013, 170, 790-798.	7.2	20
72	Lifetime endogenous reproductive factors and severe depressive symptoms in postmenopausal women. Menopause, 2013, 20, 1154-1163.	2.0	11

#	Article	IF	CITATIONS
73	Glycemia, Insulin Resistance, Insulin Secretion, and Risk of Depressive Symptoms in Middle Age. Diabetes Care, 2013, 36, 928-934.	8.6	25
74	Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression. Translational Psychiatry, 2013, 3, e322-e322.	4.8	57
75	Lifelong Estrogen Exposure and Memory in Older Postmenopausal Women. Journal of Alzheimer's Disease, 2013, 34, 601-608.	2.6	28
76	Anxiety and mortality risk in community-dwelling elderly people. British Journal of Psychiatry, 2013, 203, 303-309.	2.8	39
77	Sex Differences in the Associations Between Lipid Levels and Incident Dementia. Journal of Alzheimer's Disease, 2013, 34, 519-528.	2.6	69
78	Insomnia, Daytime Sleepiness and Cardio-Cerebrovascular Diseases in the Elderly: A 6-Year Prospective Study. PLoS ONE, 2013, 8, e56048.	2.5	49
79	Excessive Sleepiness is Predictive of Cognitive Decline in the Elderly. Sleep, 2012, 35, 1201-1207.	1.1	178
80	Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study. Journal of Alzheimer's Disease, 2012, 30, 629-637.	2.6	66
81	Anxiety symptoms and disorder predict activity limitations in the elderly. Journal of Affective Disorders, 2012, 141, 276-285.	4.1	40
82	Depression in elderly persons subject to childhood maltreatment is not modulated by corpus callosum and hippocampal loss. Journal of Affective Disorders, 2012, 141, 294-299.	4.1	10
83	Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. Neurobiology of Aging, 2012, 33, 2082-2090.	3.1	27
84	Polymorphisms of Estrogen Receptors and Risk of Depression. Drugs, 2012, 72, 1725-1738.	10.9	47
85	P-620 - Anxiety: a risk factor for the incidence of activity limitations in the elderly. European Psychiatry, 2012, 27, 1.	0.2	0
86	Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class. Journal of Clinical Epidemiology, 2012, 65, 1061-1068.	5.0	12
87	Measuring Resilience in Adult Women Using the 10-Items Connor-Davidson Resilience Scale (CD-RISC). Role of Trauma Exposure and Anxiety Disorders. PLoS ONE, 2012, 7, e39879.	2.5	141
88	Estrogen receptor alpha gene variants and major depressive episodes. Journal of Affective Disorders, 2012, 136, 1222-1226.	4.1	30
89	Hormone Treatment, Estrogen Receptor Polymorphisms and Mortality: A Prospective Cohort Study. PLoS ONE, 2012, 7, e34112.	2.5	24
90	Insomnia Symptoms in Older Adults: Associated Factors and Gender Differences. American Journal of Geriatric Psychiatry, 2011, 19, 88-97.	1.2	214

#	Article	IF	CITATIONS
91	Insomnia and Daytime Sleepiness Are Risk Factors for Depressive Symptoms in the Elderly. Sleep, 2011, 34, 1103-1110.	1.1	226
92	Estrogen receptor gene variants are associated with anxiety disorders in older women. Psychoneuroendocrinology, 2011, 36, 1582-1586.	2.7	38
93	Late life depression and incident activity limitations: Influence of gender and symptom severity. Journal of Affective Disorders, 2011, 133, 42-50.	4.1	34
94	Adverse childhood environment and late-life cognitive functioning. International Journal of Geriatric Psychiatry, 2011, 26, 503-510.	2.7	90
95	Oestrogen receptor polymorphisms and late-life depression. British Journal of Psychiatry, 2011, 199, 126-131.	2.8	31
96	Metabolic Syndrome and Onset of Depressive Symptoms in the Elderly. Diabetes Care, 2011, 34, 904-909.	8.6	56
97	Late-Life Health Consequences of Exposure to Trauma in a General Elderly Population. Journal of Clinical Psychiatry, 2011, 72, 929-935.	2.2	25
98	Neurological signs and lateâ€life depressive symptoms in a community population: the ESPRIT study. International Journal of Geriatric Psychiatry, 2010, 25, 672-678.	2.7	6
99	Caffeine, Cognitive Functioning, and White Matter Lesions in the Elderly: Establishing Causality from Epidemiological Evidence. Journal of Alzheimer's Disease, 2010, 20, S161-S166.	2.6	36
100	Long-Term Post-Operative Cognitive Decline in the Elderly: The Effects of Anesthesia Type, Apolipoprotein E Genotype, and Clinical Antecedents. Journal of Alzheimer's Disease, 2010, 22, S105-S113.	2.6	56
101	A prospective study of diurnal cortisol and cognitive function in community-dwelling elderly people. Psychological Medicine, 2010, 40, 1039-1049.	4.5	76
102	Anticholinergic drugs increase the risk of cognitive decline and dementia in older people. Evidence-Based Mental Health, 2010, 13, 44-44.	4.5	8
103	Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ: British Medical Journal, 2010, 341, c3885-c3885.	2.3	181
104	Metabolic Syndrome, Its Components, and Mortality in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E327-E332.	3.6	28
105	Retrospective Identification and Characterization of Mild Cognitive Impairment From a Prospective Population Cohort. American Journal of Geriatric Psychiatry, 2010, 18, 692-700.	1.2	25
106	Gender and Genotype Modulation of the Association Between Lipid Levels and Depressive Symptomatology in Community-Dwelling Elderly (The ESPRIT Study). Biological Psychiatry, 2010, 68, 125-132.	1.3	72
107	5-HTTLPR genotype, stressful life events and late-life depression: No evidence of interaction in a French population. Neurobiology of Aging, 2010, 31, 886-887.	3.1	28
108	A Prospective Study of Hormone Therapy and Depression in Community-Dwelling Elderly Women. Journal of Clinical Psychiatry, 2010, 71, 1673-1679.	2.2	14

#	Article	IF	CITATIONS
109	Modelling complex pathways between late-life depression and disability: evidence for mediating and moderating factors. Psychological Medicine, 2009, 39, 1587.	4.5	17
110	Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population. Archives of Internal Medicine, 2009, 169, 1317.	3.8	312
111	Characteristics of hormone therapy, cognitive function, and dementia. Neurology, 2009, 73, 1729-1737.	1.1	69
112	Persistence of abnormal cortisol levels in elderly persons after recovery from major depression. Journal of Psychiatric Research, 2009, 43, 777-783.	3.1	45
113	Life-time estrogen exposure and cognitive functioning in later life. Psychoneuroendocrinology, 2009, 34, 287-298.	2.7	93
114	A prospective study of hormonal treatment and anxiety disorders in community-dwelling elderly women (The Esprit Study). Journal of Affective Disorders, 2009, 115, 274-279.	4.1	6
115	Comparison of health insurance claims and patient interviews in assessing drug use: data from the Threeâ€City (3C) Study. Pharmacoepidemiology and Drug Safety, 2009, 18, 310-319.	1.9	83
116	Social Activity and Improvement in Depressive Symptoms in Older People: A Prospective Community Cohort Study. American Journal of Geriatric Psychiatry, 2009, 17, 688-696.	1.2	83
117	A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause, 2009, 16, 509-517.	2.0	82
118	Association of Adverse Childhood Environment and <i>5-HTTLPR</i> Genotype With Late-Life Depression. Journal of Clinical Psychiatry, 2009, 70, 1281-1288.	2.2	103
119	Abnormal reactions to environmental stress in elderly persons with anxiety disorders: Evidence from a population study of diurnal cortisol changes. Journal of Affective Disorders, 2008, 106, 307-313.	4.1	75
120	Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. Climacteric, 2008, 11, 74-83.	2.4	15
121	Risk profiles for mild cognitive impairment and progression to dementia are gender specific. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 979-984.	1.9	222
122	Hormonal treatment, mild cognitive impairment and Alzheimer's disease. International Psychogeriatrics, 2008, 20, 47-56.	1.0	49
123	Lifetime hormonal factors may predict late-life depression in women. International Psychogeriatrics, 2008, 20, 1203.	1.0	33
124	Late-life depression and mortality: influence of gender and antidepressant use. British Journal of Psychiatry, 2008, 192, 12-18.	2.8	86
125	The neuroprotective effects of caffeine. Neurology, 2007, 69, 536-545.	1.1	320
126	Is Antioxidant Therapy a Viable Alternative for Mild Cognitive Impairment? Examination of the Evidence. Dementia and Geriatric Cognitive Disorders, 2007, 24, 1-19.	1.5	42

#	Article	IF	CITATIONS
127	Hormonal therapy and depression: Are we overlooking an important therapeutic alternative?. Journal of Psychosomatic Research, 2007, 62, 473-485.	2.6	35
128	Potent Antimalarial Activity of 2-Aminopyridinium Salts, Amidines, and Guanidines. Journal of Medicinal Chemistry, 2007, 50, 6307-6315.	6.4	64
129	Mild cognitive impairment. Lancet, The, 2006, 367, 1262-1270.	13.7	2,401
130	Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ: British Medical Journal, 2006, 332, 455-459.	2.3	489
131	Lifelong Endocrine Fluctuations and Related Cognitive Disorders. Current Pharmaceutical Design, 2005, 11, 4229-4252.	1.9	51
132	Prevalence of DSM-IV psychiatric disorder in the French elderly population. British Journal of Psychiatry, 2004, 184, 147-152.	2.8	277
133	In Vivo Antimalarial Activities of Mono- and Bis Quaternary Ammonium Salts Interfering with Plasmodium Phospholipid Metabolism. Antimicrobial Agents and Chemotherapy, 2003, 47, 2598-2605.	3.2	71
134	Potent Inhibitors of Plasmodium Phospholipid Metabolism with a Broad Spectrum of In Vitro Antimalarial Activities. Antimicrobial Agents and Chemotherapy, 2003, 47, 2590-2597.	3.2	85
135	Vascular Factors and Risk of Dementia: Design of the Three-City Study and Baseline Characteristics of the Study Population. Neuroepidemiology, 2003, 22, 316-325.	2.3	570
136	A Class of Potent Antimalarials and Their Specific Accumulation in Infected Erythrocytes. Science, 2002, 295, 1311-1314.	12.6	163
137	Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. British Journal of Psychiatry, 2001, 178, 360-366.	2.8	145
138	Presence of Estrogen Receptor  in the Human Endometrium through the Cycle: Expression in Glandular, Stromal, and Vascular Cells. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1379-1386.	3.6	113
139	Antimalarial Activity of Compounds Interfering with Plasmodium falciparum Phospholipid Metabolism: Comparison between Mono- and Bisquaternary Ammonium Salts. Journal of Medicinal Chemistry, 2000, 43, 505-516.	6.4	125
140	Ionophore–Phospholipid Interactions in Langmuir Films in Relation to Ionophore Selectivity toward Plasmodium-Infected Erythrocytes. Journal of Colloid and Interface Science, 1999, 218, 377-387.	9.4	9
141	Cationomycin and Monensin Partition between Serum Proteins and Erythrocyte Membrane: Consequences for Na+and K+Transport and Antimalarial Activities. Archives of Biochemistry and Biophysics, 1999, 363, 361-372.	3.0	13
142	Continuous in vitro culture of Babesia divergens in a serum-free medium. Parasitology, 1997, 115, 81-89.	1.5	34
143	Plasmodium falciparum CTP:phosphocholine cytidylyltransferase expressed in Escherichia coli: purification, characterization and lipid regulation. Biochemical Journal, 1997, 324, 903-910.	3.7	32
144	Plasmodium phospholipid metabolism: a target for the development of novel antimalarial drugs. Annals of Tropical Medicine and Parasitology, 1997, 91, S87-S90.	1.6	0

#	Article	IF	CITATIONS
145	Antimalarial Activity of Molecules Interfering with Plasmodium falciparum Phospholipid Metabolism. Structureâ^'Activity Relationship Analysis. Journal of Medicinal Chemistry, 1997, 40, 3557-3566.	6.4	101
146	Characterization of phosphatidylinositol synthase and evidence of a polyphosphoinositide cycle in Plasmodium-infected erythrocytes. Molecular and Biochemical Parasitology, 1994, 63, 179-192.	1.1	43
147	Present development concerning antimalarial activity of phospholipid metabolism inhibitors with special reference to in vivo activity. Memorias Do Instituto Oswaldo Cruz, 1994, 89, 85-90.	1.6	4
148	Infected erythrocyte choline carrier inhibitors: exploring some potentialities inside Plasmodium phospholipid metabolism for eventual resistance acquisition. Memorias Do Instituto Oswaldo Cruz, 1994, 89, 91-97.	1.6	2
149	Use of radioactive ethanolamine incorporation into phospholipids to assess in vitro antimalarial activity by the semiautomated microdilution technique. Antimicrobial Agents and Chemotherapy, 1992, 36, 50-55.	3.2	58
150	An original method for rapid serial determination of phospholipid biosynthesis. Applications to mammalian lymphocytic cells and a lower eucaryote, Plasmodium falciparum. Analytical Biochemistry, 1991, 199, 203-209.	2.4	5
151	Phospholipid asymmetry in the plasma membrane of malaria infected erythrocytes. Biochemistry and Cell Biology, 1990, 68, 579-585.	2.0	34
152	Selective elimination of malaria infected erythrocytes by a modified phospholipase A2 in vitro. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1024, 189-192.	2.6	27
153	Regulation of phosphatidylcholine biosynthesis in Plasmodium-infected erythrocytes. Lipids and Lipid Metabolism, 1989, 1001, 82-89.	2.6	54
154	Phospholipid metabolism in <i>Plasmodium</i> -infected erythrocytes: guidelines for further studies using radioactive precursor incorporation. Parasitology, 1989, 98, 351-357.	1.5	27
155	Differential effects of chloroquine on the phospholipid metabolism of plasmodium-infected erythrocytes. Biochemical Pharmacology, 1988, 37, 3139-3147.	4.4	4
156	Phospholipid uptake byPlasmodium knowlesiinfected erythrocytes. FEBS Letters, 1988, 232, 341-346.	2.8	41
157	Choline Incorporation by Schistosoma mansoni: Distribution of Choline Metabolites during Development and after Sexual Differentiation. Journal of Parasitology, 1987, 73, 530.	0.7	9
158	Choline kinase activity in Plasmodium-infected erythrocytes: characterization and utilization as a parasite-specific marker in malarial fractionation studies. Lipids and Lipid Metabolism, 1986, 875, 52-58.	2.6	26
159	Several lines of evidence demonstrating thatPlasmodium falciparum, a parasitic organism, has distinct enzymes for the phosphorylation of choline and ethanolamine. FEBS Letters, 1986, 202, 217-223.	2.8	36
160	Quaternary ammonium compounds efficiently inhibit Plasmodium falciparum growth in vitro by impairment of choline transport. Antimicrobial Agents and Chemotherapy, 1986, 29, 814-820.	3.2	71
161	Renewal of the membrane complex of Schistosoma mansoni is closely associated with lipid metabolism. Molecular and Biochemical Parasitology, 1985, 17, 203-218.	1.1	14
162	Inhibitors of choline transport into Plasmodium-infected erythrocytes are effective antiplasmodial compounds in vitro. Biochemical Pharmacology, 1985, 34, 4068-4071.	4.4	40

#	Article	IF	CITATIONS
163	Phospholipid metabolism as a new target for malaria chemotherapy. Mechanism of action of D-2-amino-1-butanol. Biochemical Pharmacology, 1984, 33, 2761-2770.	4.4	38